Skip to main content
. 2022 Feb 17;14:818597. doi: 10.3389/fnagi.2022.818597

TABLE 1.

Demographic characteristics of all enrolled participants.

Variables All participants
pa values PD
pb values
PD HC H-Y I H-Y II H-Y III
Eyes, N 115 67 NA 50 46 19 NA
Age, y 63.61 ± 6.92 62.01 ± 7.74 0.151* 62.08 ± 6.73 65.35 ± 7.07 63.47 ± 6.41 0.068
Sex, male, N (%) 51.00 (44.35%) 29.00 (43.28%) 0.889 19.00 (38.00%) 24.00 (52.20%) 8.00 (42.10%) 0.369
IOP, mmHg 15.53 ± 2.02 15.36 ± 2.07 0.583* 15.42 ± 2.19 15.74 ± 1.97 15.32 ± 1.67 0.655
SBP, mmHg 141.2 ± 19.31 142.6 ± 20.53 0.645* 140.7 ± 20.47 141.2 ± 18.98 142.7 ± 17.83 0.931
BCVA, logMAR 0.35 ± 0.13 0.35 ± 0.13 0.839* 0.33 ± 0.13 0.35 0.13 0.38 ± 0.13 0.478
AL, mm 21.97 ± 0.57 22.06 ± 0.60 0.357* 21.94 ± 0.57 22.01 ± 0.56 21.98 ± 0.63 0.826
Duration, y 6.00 (4.00–8.00) NA NA 4.00 (3.00–6.00) 7.00 (5.00–9.00) 9.00 (7.00–12.00) <0.001 **
UPDRS 33.00 (22.00–54.00) NA NA 20.50 (12.75–26.25) 44.50 (31.75–56.00) 69.00 (55.00–76.00) <0.001 **
UPDRS III 17.00 (11.00–31.75) NA NA 11.00 (6.75–15.00) 27.50 (17.75–37.25) 45.00 (34.00–54.00) <0.001 **
NMSS 20.50 (9.00–43.75) NA NA 14.00 (6.00–23.50) 35.50 (15.75–50.00) 41.00 (27.00–75.00) <0.001 **
MMSE 28.00 (26.00–29.00) NA NA 28.00 (27.00–30.00) 27.00 (25.75–29.00) 26.50 (23.50–29.00) 0.012 **

Significant results appear in bold. pa: p-value for comparison between HC and PD; pb: p-value for comparison among the three PD subgroups. *Student’s t-test; Pearson’s χ2 test; One-way ANOVA; **Non-parametric test.

PD, Parkinson’s Disease; HC, healthy controls; IOP, intraocular pressure; SBP, systolic blood pressure; BCVA, best-corrected visual acuity; AL, axial lengths; UPDRS, Unified Parkinson’s Disease Rating Scale; UPDRS III, Unified Parkinson’s Disease Rating Scale III; NMSS, Non-motor Symptoms Scale; MMSE, Mini-Mental State Examination.